Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex extends its Cloe® Screen Mechanism-Based Inhibition service to include an additional cytochrome P450 isoform, CYP2C8

Today, (23rd March 2010), Cyprotex extends its Cloe® Screen Mechanism-Based Inhibition service to include the cytochrome P450 isoform, CYP2C8. Cyprotex now offer an extensive range of validated assays to evaluate mechanism based inhibition for a panel of the major cytochrome P450 isoforms. The importance of CYP2C8 in clinical drug-drug interactions has been recognised within the industry and it is now recommended that in vitro evaluation is performed to establish the likelihood of potential interactions for this isoform (Huang et al., 2008). The panel of cytochrome P450 isoforms offered in the Cloe® Screen Mechanism-Based Inhibition service is also now consistent with our Cloe® Screen Cytochrome P450 Inhibition service. By using the Cloe® Screen Mechanism-Based Inhibition assays in conjunction with our existing Cloe® Screen CYP450 inhibition assays, it is possible to investigate both reversible and irreversible inhibition. Used in combination, these assays act as valuable tools in identifying potential drug-drug interactions.

The inhibition of human cytochrome P450 enzymes is one of the most common mechanisms that can lead to drug-drug interactions and ultimately potential toxic effects. Although less common, irreversible interactions such as mechanism-based inhibition are considered to be more serious than reversible inhibition because the inactivated enzyme must be re-synthesised before activity is restored. The impact of mechanism-based inhibition is now recognised within the Pharmaceutical Industry and draft FDA regulatory guidelines recommend screening for these interactions, in vitro, as part of the drug discovery process.

Dr. Anthony Baxter, Cyprotex’s Chief Executive Officer, comments on the launch of this new service.

“Selecting candidates with a minimum potential of inhibition of cytochrome P450 is critical in avoiding late stage issues or failures. Evaluation of drug-drug interactions is an important part of our business and Cyprotex offer a comprehensive range of drug-drug interaction services which span both drug discovery and drug development. All our new services are fully validated ensuring a high level of data quality for our clients.”

For further information:

Cyprotex PLC
Swadipa Das, Marketing Manager
Tel: +44 1625 505 100
s.das@cyprotex.com
www.cyprotex.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close